ADMA Biologics Inc $ADMA Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC lessened its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 71.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 79,622 shares of the biotechnology company’s stock after selling 196,333 shares during the quarter. Lisanti Capital Growth LLC’s holdings in ADMA Biologics were worth $1,167,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $25,000. Cullen Frost Bankers Inc. boosted its holdings in ADMA Biologics by 112.5% in the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,081 shares during the period. Ameritas Advisory Services LLC purchased a new position in shares of ADMA Biologics in the 2nd quarter valued at about $46,000. EverSource Wealth Advisors LLC lifted its stake in ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,180 shares during the last quarter. Finally, Blue Trust Inc. lifted its position in shares of ADMA Biologics by 53.6% during the 2nd quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 964 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $17.30 on Friday. The stock has a 50 day simple moving average of $18.57 and a 200-day simple moving average of $17.04. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 20.12 and a beta of 0.47. The company has a current ratio of 7.13, a quick ratio of 3.65 and a debt-to-equity ratio of 0.18. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The company had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. During the same period last year, the company posted $0.15 earnings per share. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. On average, equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.